Non-small-cell lung cancer with HER2 exon 20 mutation: Regression with dual HER2 inhibition and anti-vegf combination treatment

Gerald S. Falchook; Filip Janku; Anne S. Tsao; Christel C. Bastida; David J. Stewart; Razelle Kurzrock

doi:10.1097/JTO.0b013e31827ce38e

Non-small-cell lung cancer with HER2 exon 20 mutation: Regression with dual HER2 inhibition and anti-vegf combination treatment

Gerald S. Falchook, Filip Janku, Anne S. Tsao, Christel C. Bastida, David J. Stewart, Razelle Kurzrock

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	e19-e20
Journal	Journal of Thoracic Oncology
Volume	8
Issue number	2
DOIs	https://doi.org/10.1097/JTO.0b013e31827ce38e
State	Published - Feb 2013

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1097/JTO.0b013e31827ce38e

Cite this

@article{1e0287cc841041158d1c2b11bb441194,

title = "Non-small-cell lung cancer with HER2 exon 20 mutation: Regression with dual HER2 inhibition and anti-vegf combination treatment",

author = "Falchook, {Gerald S.} and Filip Janku and Tsao, {Anne S.} and Bastida, {Christel C.} and Stewart, {David J.} and Razelle Kurzrock",

note = "Funding Information: Supported by grant number RR024148 from the National Center for Research Resources, a component of the NIH Roadmap for Medical Research ( http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp ). All treatment regimens given and data analyses were performed in accordance with M.D. Anderson Institutional Review Board guidelines. We thank Jenny Jiang for clinical trial coordination and Joann Aaron for scientific review and editing of this article. Funding Information: Disclosure: Gerald S. Falchook, Filip Janku, and Razelle Kurzrock receive research funding from GlaxoSmithKline. ",

year = "2013",

month = feb,

doi = "10.1097/JTO.0b013e31827ce38e",

language = "English (US)",

volume = "8",

pages = "e19--e20",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "2",

}

TY - JOUR

T1 - Non-small-cell lung cancer with HER2 exon 20 mutation

T2 - Regression with dual HER2 inhibition and anti-vegf combination treatment

AU - Falchook, Gerald S.

AU - Janku, Filip

AU - Tsao, Anne S.

AU - Bastida, Christel C.

AU - Stewart, David J.

AU - Kurzrock, Razelle

N1 - Funding Information: Supported by grant number RR024148 from the National Center for Research Resources, a component of the NIH Roadmap for Medical Research ( http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp ). All treatment regimens given and data analyses were performed in accordance with M.D. Anderson Institutional Review Board guidelines. We thank Jenny Jiang for clinical trial coordination and Joann Aaron for scientific review and editing of this article. Funding Information: Disclosure: Gerald S. Falchook, Filip Janku, and Razelle Kurzrock receive research funding from GlaxoSmithKline.

PY - 2013/2

Y1 - 2013/2

UR - http://www.scopus.com/inward/record.url?scp=84873830350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873830350&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31827ce38e

DO - 10.1097/JTO.0b013e31827ce38e

M3 - Article

C2 - 23328556

AN - SCOPUS:84873830350

SN - 1556-0864

VL - 8

SP - e19-e20

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 2

ER -

Non-small-cell lung cancer with HER2 exon 20 mutation: Regression with dual HER2 inhibition and anti-vegf combination treatment

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this